New tablet attaches to the lining of the GI tract, resists being pulled away
Researchers from MIT and Brigham and Women’s Hospital have designed a new type of pill that, once swallowed, can attach to the lining of the gastrointestinal tract and slowly release its contents. The tablet is engineered so that one side adheres to tissue, while the other repels food and liquids that would otherwise pull it away from the attachment site.
Such extended-release pills could be used to reduce the dosage frequency of some drugs, the researchers say. For example, antibiotics that normally have to be taken two or three times a day could be given just once, making it easier for patients to stick to their dosing schedule.
“This could be adapted to many drugs. Any drug that is dosed frequently could be amenable to this kind of system,” says Giovanni Traverso, a research affiliate at MIT’s Koch Institute for Integrative Cancer Research, a gastroenterologist at Brigham and Women’s Hospital, and one of the senior authors of a paper describing the device in the April 6 issue of the journal Advanced Healthcare Materials.
Robert Langer, the David H. Koch Institute Professor and a member of the Koch Institute, is also a senior author of the paper. The paper’s lead author is Young-Ah Lucy Lee, a technical assistant at the Koch Institute.
Over the past several decades, Langer’s lab has developed many types of materials that can be implanted in the body or attached to the skin for long-term drug release. To achieve similar, long-term drug release in the gastrointestinal tract, the researchers focused on a type of material known as mucoadhesives, which can stick to the mucosal linings of organs such as the stomach.
Scientists have previously explored using this kind of material for drug delivery to the GI tract, but it has proven difficult because food and liquid in the stomach become stuck to the tablet, pulling it away from the tissue before it can deliver its entire drug payload.
“The challenge with mucoadhesives is that the GI tract is a very rough and abrasive environment,” says Lee, a 2014 Wellesley College graduate who began this project as her senior thesis.
To overcome this challenge, the researchers decided to create a dual-sided device, also called a Janus device after the two-faced Roman god. One side sticks to mucosal surfaces, while the other is omniphobic, meaning that it repels everything it encounters.
For the mucoadhesive side, the researchers used a commercially available polymer known as Carbopol, which is often used industrially as a stabilizing or thickening agent. The omniphobic side consists of cellulose acetate that the researchers textured so that its surface would mimic that of a lotus leaf, which has micro and nanoscale protrusions that make it extremely hydrophobic. They then fluorinated and lubricated the surface, making it repel nearly any material.
The researchers used a pill presser to combine the polymers into two-sided tablets, which can be formed in many shape and sizes. Drugs can be either embedded within the cellulose acetate layer or placed between the two layers.
Using intestinal tissue from pigs, the researchers tested three versions of the tablet — a dual-sided mucoadhesive tablet, a dual-sided omniphobic tablet, and the Janus version, with one mucoadhesive side and one omniphobic side.
To simulate the tumultuous environment of the GI tract, the researchers flowed a mix of food including liquids and small pieces of bread and rice along the tissue and then added the tablets. The dual-sided omniphobic tablet took less than 1 second to travel along the tissue, and the dual-sided mucoadhesive stuck to the tissue for only 7 seconds before being pulled off. The Janus version stayed attached for the length of the experiment, about 10 minutes.
Tejal Desai, a professor of bioengineering and therapeutic sciences at the University of California at San Francisco, says this approach could make it possible to deliver larger quantities of drugs through the GI tract.
“The ability to precisely engineer the adhesiveness of a particle opens up possibilities of designing particles to selectively adhere to specific regions of the GI tract, which in turn can increase the local or systemic concentrations of a particular drug,” says Desai, who was not involved in the work.
The researchers now plan to do further tests in animals to help them tune how long the tablets can stay attached, the rate at which drugs are released from the material, and the ability to target the material to specific sections of the GI tract.
In addition to delivering antibiotics, the two-sided material may help to simplify drug regimens for malaria or tuberculosis, among other diseases, Traverso says. The researchers may also further pursue the development of tablets with omniphobic coatings on both sides, which they believe could help patients who have trouble swallowing pills.
“There are certain medications that are known to get stuck, particularly in the esophagus. It causes this massive amount of inflammation because it gets stuck and it causes irritation,” Traverso says. “Texturing the surfaces really opens up a new way of thinking about controlling and tuning how these drug formulations travel.”
The Latest on: Long-term drug release
via Google News
The Latest on: Long-term drug release
- Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis on April 18, 2019 at 2:05 pm
The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs ... This press release features ... […]
- Churchill Downs, Keeneland join phased ban on controversial horse racing drug on April 18, 2019 at 11:23 am
The use of the drug has been debated ... essential step as we look toward the long-term sustainability of U.S.-breds on the national and international stage," Keeneland President and CEO Bill Thomason ... […]
- Experimental drug designed to help sway opioid cravings on April 18, 2019 at 6:47 am
Opioid use causes a surge of the neurotransmitter dopamine in the brain, the release said ... equipment or drug use partners. The NIAID is helping to conduct the trial, which is funded through NIH's ... […]
- DEA launching 360 Strategy to fight drugs, crime in New Orleans area on April 16, 2019 at 2:26 pm
NEW ORLEANS (WVUE) - The Drug Enforcement ... the core of a long-term group that will cross disciplines to help carry the prevention and treatment messages to the local population during the critical ... […]
- Common Diabetes Drug May Also Help Kidneys, Heart on April 16, 2019 at 9:14 am
MONDAY, April 15, 2019 (HealthDay News) -- A common diabetes drug may also greatly reduce the odds for death ... preserving kidney function for years longer than we thought possible for the long term, ... […]
- Joint Press Release: Europe-Africa partnership spearheads development of next-generation antimalarial drug on April 15, 2019 at 12:39 pm
The European & Developing Countries Clinical Trials Partnership (EDCTP) (www.EDCTP.org) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers . ... […]
- Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy on April 12, 2019 at 2:19 am
The in situ released CPT acts as a cellular respiration inhibitor, inducing mtROS upregulation, thus achieving subsequent self-circulation of CPT release and mtROS burst. This mtROS amplification ... […]
- 3 arrested after long-term task force drug investigation, search warrant on April 11, 2019 at 5:33 am
Urbana teacher fired after sending text with principal’s face on shooting range target The search was executed at a house in the 1600 block of West Grand Avenue following a long-term investigation ... […]
- Controlled Release Drug Delivery Market to witness excellent Long-Term Growth Outlook by Alkermes, Pfizer, Orbis Biosciences on April 10, 2019 at 3:35 am
Apr 10, 2019 (AB Digital via COMTEX) -- Some of the Leading key Company’s Covered for this Research are Depomed, Coating Place, Corium, Johnson and Johnson, Alkermes, Pfizer, Orbis Biosciences, ... […]
- Man tied to drug-trafficking organization gets 1 year in complex peso exchange scheme on April 8, 2019 at 7:15 pm
In court Monday, Esteban Guillen Ramirez, 53, was also sentenced to three years of supervised release ... and Vancouver areas following the long-term heroin trafficking investigation. Agents arrested ... […]
via Bing News